A4544840 7708 43a7 95ec 7482241e67a3 01
Anastrozole Tablet, Coated
Product Images NDC 68382-209
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Anastrozole (NDC 68382-209). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Zydus Pharmaceuticals Usa Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Product Images & Figures Index
A4544840 7708 43a7 95ec 7482241e67a3 02
This appears to be a chart or graph with the title "Proportion alive and disease-free". The horizontal axis represents "disease-free survival in months" and the vertical axis appears to represent the proportion of patients who are alive and disease-free. There are two treatment options being compared, but the names are not entirely legible due to inaccuracies. It appears one treatment option may be "tamodfen" or "tamoten" and the other option may be "anastrozole". The chart includes data points for each treatment option at various intervals of disease-free survival, possibly indicating the proportion of patients on each treatment who remain alive and disease-free after that amount of time.*
A4544840 7708 43a7 95ec 7482241e67a3 03
This table is showing the comparison of disease-free survival in months between two randomized treatments. The treatments are mentioned as anastrozole and anasromole. At the bottom, the number of patients at risk is given. *
A4544840 7708 43a7 95ec 7482241e67a3 04
This appears to be a graph or chart of a medical study comparing randomized treatment using anastrozole and tamoxifen. The x-axis measures time to event in months, while the y-axis is labeled "PROPORTION EVENT FREE" with values ranging from 0 to 1. The chart shows two lines representing the two treatments that converge and diverge over time. There is also a note at the bottom explaining that the vertical axis has been truncated to improve the clarity of the graph.*
A4544840 7708 43a7 95ec 7482241e67a3 05
The text is a graph showing the proportion of event-free patients over time (in months) for a randomized treatment with anastrozole and tamoxifen. The number of patients at risk is also provided. The vertical axis has been truncated for clarity.*
A4544840 7708 43a7 95ec 7482241e67a3 06
This appears to be a graph showing the time to progression of randomized treatments (Anastrozole and Tamoxifen) over a certain period of months. The number of patients at risk for each treatment is also provided.*
A4544840 7708 43a7 95ec 7482241e67a3 07
The text describes a graph that shows the time to progression in months for randomized treatments, Anastrolze and Tamoxifen. However, the proportion is not progressing.*
A4544840 7708 43a7 95ec 7482241e67a3 08
This is a product description for Anastrozole B tablets. The tablets are USP controlled and come in a container that is resistant to dipersing and resistntand. The recommended storage temperature is between 25- 68" 77°F. The product is manufactured by Codls Hearars 1. Fid Bemacie, gz and distributed by 1,000 TABLETS et USA at 7t 2ydus Reony rosgm gt. The product label warns to keep all drugs out of reach of children.*
* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.
